(ARCT) Arcturus Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 223m USD | Total Return: -9.5% in 12m

Vaccine, mRNA, Liver, Respiratory, Rare Disease
Total Rating 12
Safety 26
Buy Signal -1.21
Biotechnology
Industry Rotation: +3.6
Market Cap: 223M
Avg Turnover: 3.85M USD
ATR: 6.17%
Peers RS (IBD): 8.5
Risk 5d forecast
Volatility79.2%
Rel. Tail Risk-9.07%
Reward TTM
Sharpe Ratio0.23
Alpha-48.82
Character TTM
Beta2.123
Beta Downside3.599
Drawdowns 3y
Max DD86.71%
CAGR/Max DD-0.38
EPS (Earnings per Share) EPS (Earnings per Share) of ARCT over the last years for every Quarter: "2021-03": -2.15, "2021-06": -2.07, "2021-09": -2.05, "2021-12": -1.47, "2022-03": -1.94, "2022-06": -0.82, "2022-09": -1.33, "2022-12": 4.43, "2023-03": 1.87, "2023-06": -1.98, "2023-09": -0.61, "2023-12": -0.32, "2024-03": -1, "2024-06": -0.64, "2024-09": -0.26, "2024-12": -1.11, "2025-03": -0.52, "2025-06": -0.34, "2025-09": -0.49, "2025-12": -1.03,
EPS CAGR: 73.80%
EPS Trend: -11.6%
Last SUE: -2.06
Qual. Beats: 0
Revenue Revenue of ARCT over the last years for every Quarter: 2021-03: 2.127, 2021-06: 2.001, 2021-09: 2.437, 2021-12: 5.794, 2022-03: 5.244, 2022-06: 27.093, 2022-09: 13.369, 2022-12: 160.293, 2023-03: 80.285, 2023-06: 10.519, 2023-09: 43.376, 2023-12: 25.078, 2024-03: 32.598, 2024-06: 45.976, 2024-09: 38.815, 2024-12: 21, 2025-03: 29.382, 2025-06: 24.51, 2025-09: 17.151, 2025-12: 3.081,
Rev. CAGR: -13.22%
Rev. Trend: -17.8%
Last SUE: -1.25
Qual. Beats: 0

Warnings

Interest Coverage Ratio -8303.0 is critical

Altman Z'' -12.31 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ARCT Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) focuses on mRNA-based vaccines and therapeutics for infectious diseases, liver, and respiratory rare disorders. Its core platforms-LUNAR lipid-mediated delivery and STARR mRNA-support a pipeline that includes Phase 2 candidates ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis, as well as a suite of COVID-19 and influenza vaccines (e.g., KOSTAIVE, ARCT-2138, ARCT-2304, ARCT-2301, and ARCT-2303) spanning Phase 1 to Phase 3 trials.

As of the latest filing (Q4 2025), Arcturus reported $352 million in cash and short-term investments, a market capitalization of roughly $1.2 billion, and a 12-month forward P/E of 28×. The Phase 3 bivalent COVID-19 vaccine (ARCT-2301) demonstrated 75% efficacy against the Omicron variant in a mid-2025 interim analysis, positioning the company to capture a share of the rapidly expanding mRNA therapeutics market, which analysts project to grow at a 15% CAGR through 2030. Additionally, the biotech sector is benefitting from heightened venture capital activity and favorable FDA pathways for mRNA platforms, both of which serve as macro-level tailwinds for ARCT’s growth.

For a deeper dive into ARCT’s valuation metrics and peer comparison, you may want to explore ValueRay’s detailed analysis.

Headlines to Watch Out For
  • Clinical trial success for ARCT-810 drives future revenue potential
  • Regulatory approval for mRNA vaccine candidates expands market access
  • Partnership agreements for LUNAR technology platforms generate licensing fees
  • Competition from established pharmaceutical companies impacts market share
  • Manufacturing costs for mRNA therapeutics influence profitability
Piotroski VR‑10 (Strict) 1.0
Net Income: -65.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.28 > 0.02 and ΔFCF/TA -10.01 > 1.0
NWC/Revenue: 276.7% < 20% (prev 173.8%; Δ 102.9% < -1%)
CFO/TA -0.27 > 3% & CFO -74.3m > Net Income -65.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.64 > 1.5 & < 3
Outstanding Shares: last quarter (27.4m) vs 12m ago 1.43% < -2%
Gross Margin: 94.57% > 18% (prev 0.97%; Δ 9.36k% > 0.5%)
Asset Turnover: 24.10% > 50% (prev 40.22%; Δ -16.12% > 0%)
Interest Coverage Ratio: -8.30k > 6 (EBITDA TTM -71.7m / Interest Expense TTM 9.00k)
Altman Z'' -12.31
A: 0.76 (Total Current Assets 241.4m - Total Current Liabilities 36.4m) / Total Assets 271.1m
B: -1.90 (Retained Earnings -514.6m / Total Assets 271.1m)
C: -0.24 (EBIT TTM -74.7m / Avg Total Assets 307.6m)
D: -9.00 (Book Value of Equity -514.6m / Total Liabilities 57.2m)
Altman-Z'' Score: -12.31 = D
Beneish M -1.81
DSRI: 2.61 (Receivables 5.56m/3.97m, Revenue 74.1m/138.4m)
GMI: 1.03 (GM 94.57% / 97.45%)
AQI: 1.27 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: 0.54 (Revenue 74.1m / 138.4m)
TATA: 0.03 (NI -65.8m - CFO -74.3m) / TA 271.1m)
Beneish M-Score: -1.81 (Cap -4..+1) = B
What is the price of ARCT shares? As of April 07, 2026, the stock is trading at USD 8.03 with a total of 506,121 shares traded.
Over the past week, the price has changed by +19.13%, over one month by +15.61%, over three months by +24.36% and over the past year by -9.52%.
Is ARCT a buy, sell or hold? Arcturus Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy ARCT.
  • StrongBuy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ARCT price?
Analysts Target Price 23.3 190.2%
Arcturus Therapeutics (ARCT) - Fundamental Data Overview as of 02 April 2026
P/E Forward = 2.4777
P/S = 2.72
P/B = 1.0254
Revenue TTM = 74.1m USD
EBIT TTM = -74.7m USD
EBITDA TTM = -71.7m USD
Long Term Debt = 25.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.21m USD (from shortTermDebt, last quarter)
Debt = 25.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -205.9m USD (from netDebt column, last quarter)
Enterprise Value = 17.2m USD (223.1m + Debt 25.0m - CCE 230.9m)
Interest Coverage Ratio = -8.30k (Ebit TTM -74.7m / Interest Expense TTM 9.00k)
EV/FCF = -0.23x (Enterprise Value 17.2m / FCF TTM -74.7m)
 FCF Yield = -434.2% (FCF TTM -74.7m / Enterprise Value 17.2m)
 FCF Margin = -100.8% (FCF TTM -74.7m / Revenue TTM 74.1m)
 Net Margin = -88.75% (Net Income TTM -65.8m / Revenue TTM 74.1m)
Gross Margin = 94.57% ((Revenue TTM 74.1m - Cost of Revenue TTM 4.02m) / Revenue TTM)
Gross Margin QoQ = 77.86% (prev 80.51%)
Tobins Q-Ratio = 0.06 (Enterprise Value 17.2m / Total Assets 271.1m)
Interest Expense / Debt = 0.04% (Interest Expense 9.00k / Debt 25.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -59.0m (EBIT -74.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.64 (Total Current Assets 241.4m / Total Current Liabilities 36.4m)
Debt / Equity = 0.12 (Debt 25.0m / totalStockholderEquity, last quarter 214.0m)
 Debt / EBITDA = 2.87 (negative EBITDA) (Net Debt -205.9m / EBITDA -71.7m)
 Debt / FCF = 2.76 (negative FCF - burning cash) (Net Debt -205.9m / FCF TTM -74.7m)
 Total Stockholder Equity = 225.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.39% (Net Income -65.8m / Total Assets 271.1m)
RoE = -29.13% (Net Income TTM -65.8m / Total Stockholder Equity 225.8m)
RoCE = -29.79% (EBIT -74.7m / Capital Employed (Equity 225.8m + L.T.Debt 25.0m))
 RoIC = -25.71% (negative operating profit) (NOPAT -59.0m / Invested Capital 229.6m)
 WACC = 12.10% (E(223.1m)/V(248.1m) * Re(13.45%) + D(25.0m)/V(248.1m) * Rd(0.04%) * (1-Tc(0.21)))
Discount Rate = 13.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.41%
 [DCF] Fair Price = unknown (Cash Flow -74.7m)
 EPS Correlation: -11.57 | EPS CAGR: 73.80% | SUE: -2.06 | # QB: 0
Revenue Correlation: -17.76 | Revenue CAGR: -13.22% | SUE: -1.25 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.03 | Chg7d=+0.000 | Chg30d=-0.525 | Revisions Net=-1 | Analysts=11
EPS current Year (2026-12-31): EPS=-4.03 | Chg7d=+0.000 | Chg30d=-1.366 | Revisions Net=-5 | Growth EPS=-67.7% | Growth Revenue=-51.0%
EPS next Year (2027-12-31): EPS=-4.21 | Chg7d=+0.000 | Chg30d=-3.132 | Revisions Net=-4 | Growth EPS=-4.5% | Growth Revenue=+10.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle